# Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation

> **NCT03523520** · PHASE4 · COMPLETED · sponsor: **University of Missouri-Columbia** · enrollment: 15 (actual)

## Conditions studied

- Constipation Drug Induced

## Interventions

- **DRUG:** Methylnaltrexone Bromide 150 mg Oral Tablet
- **DRUG:** Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1
- **DRUG:** Naloxegol 25 MG Oral Tablet

## Key facts

- **NCT ID:** NCT03523520
- **Lead sponsor:** University of Missouri-Columbia
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-23
- **Primary completion:** 2023-03-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03523520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03523520, "Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03523520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*